The bystander effect of payloads like DXd enables trastuzumab deruxtecan to effectively target HER2-heterogeneous breast cancers, achieving objective response rates of up to 70% in pretreated HER2-positive disease and over 50% in HER2-low tumors [117]. This evidence concerns the gene ERBB2 and breast carcinoma.